Bristol-Myers Squibb is buying Celgene in a $74 billion deal

Advertisement
Bristol-Myers Squibb is buying Celgene in a $74 billion deal

Bristol-Myers Squibb

Brendan McDermid/Reuters

Advertisement
  • Bristol-Myers Squibb has agreed to acquire Celgene, the drugmakers announced Thursday in a deal valued at $74 billion.
  • The deal will pay Celgene shareholders 1 Bristol-Myers Squibb share and $50 cash for each Celgene share they own.
  • The deal combines a massive pharmaceutical company with a biotech giant, both of which have a big presence in cancer drug development.
  • Watch Celgene and BMS trade in real time.

NOW WATCH: An exercise scientist reveals exactly how long you need to work out to get in great shape

{{}}
Next StoryA 20-year Wall Street veteran has joined distressed debt shop Marathon as the market for troubled companies heats up